, , ,

<<


 >>  ()
Pages:     | 1 | 2 || 4 | 5 |   ...   | 8 |

616-006-053.2-07-08 . 3 . . 2. ...

-- [ 3 ] --

. 30-40 % [ 1 8 8 - 1 9 0 ]. 80- X X . A T R A, PMURARa, [ 1 9 1, 1 9 2, 1 9 3 ]. , ( A T R A ), 79 97 %, 64-76 % [194-199]. A T R A . , , , [200]. , 6-, ATRA, [201].

. ( (!) ) . 5 0 % 20 % , . , d e novo, , / , [14].

, -, - , , t ( 8 ;

2 1 ) ( q 2 2 ;

q 2 2 ), inv16(p13q22), t(16;

16)(p13;

q22), 11q23. [14].

, , therapy-related ˻, , . F A B - , [14].

( F A B - ) 9-12 % [202]. (. 56). . , . , . , , , . (L2). , , .

(FAB- 1) 16 2 6 % [ 2 0 2 ]. 1 ( ) (. 57, 58) . , , , , (10 %) , , , ( . . 6 5, 6 7 ), P A S - . (90 % ), , 3 % , [ 1 4 ].

( F A B - 2) 20-29 % . 2 (. 59) , , , , . . , , 1, ( ), , , . 1, 2 . 2 . [14] 20 % , ( , 1 0 % ), 2 0 % ( F A B - ) 1 6 % [202]. , . [14]. - , , , , , . : 1 - ( 60);

2 - ( M 3 v F A B - , 1 5 - 2 0 % ) , , [203] (. 61). (. 6 6, 67), P A S - - (. 70). 25 % (. 68).

( F A B - 4) 1 6 - 3 3 % [202]. (4) : ( 1 2 ) ( 5 5 ), (. 62). . [14] 20 % , 2 0 % , 2 0 % . 3 % . , , .

FAB- 4 5 % , 4. 4 , . .

. 68. , 69 , . 70. PAS- , ( F A B - 5) 9-26 % [ 2 0 2 ]. 5 (), t(8;

16)(p11;

p13) [ 2 0 4 ] 5 ( 5 ) (5) , , 1-2 , ( . . 63). . : 5 , 5 - . [14] (80 % , , - 20 % ).

( 5 ) (80 %) , ( 5) - . , , , . , ( . . 6 8, 69). 20 % . .

(FAB- ) 1 - 4 % [202], . (, , ). : 1 ( . . 64). [ 1 4 ] :

1) , 5 0 % 2 0 % ;

2) , ( 8 0 % ) .

( F A B - 7) 0-2 % [ 2 0 2 ]. , . , - , . . , . , PAS- . 50 % [14] / . 1-3 . [205].

FAB . 15. ( . . 6 5, 6 6 ) / (. . 6 7 ). - - ( . . 6 8, 6 9 ). (. . 70).

, ( , ) ( , , ), , [14].

. [14], , , .

- (), , , - - - .

[ 1 4 ].

- , , , .

, . , , . , C D 6 8 [14].

FAB- PAS * - / + NaF - - + + + 1 + -/+ + ++ ++ +-/+ ++ ++ +-/+ ++ ++/ + + + ++/ MS * +/+ + ++/++ 7 : - - ;

+ - (, 3 % );

- ;

PAS- .

* .

, , - - [ 2 0 6 ]. C D 3 H L A - D R, . C D 1 3 . C D 1 , . - .

, F A B - , FAB- [206]. . , - , [206].

( E G I L - 9 5 [53]) .

1. :

+, C D 1 3 +, C D 3 3 +, C D 6 5 +, / C D 1 1 7 + (c-kit), C D 1 ( ).

2. ( , ) :

/ : ;

: +.

3. (7):

C D 4 1 + / C D 6 1 + ( ).

4. (). . , CD3, CD79a, CD22.

5. T d T - .

6. ( ).

: , C D 1 3, C D 1 5, C D 3 3, CD65, CD117. , , ( F A B - , 1, 2, ) ( 4, 5 ). , (4) (5) C D 1 4, 5 CD14 [100, 207]. 4 5 HLA-DR, CD11c CD15, CD4 , .

( F A B - ) ( C D 1 3, C D 3 3, C D 1 1 7 ), C D 3 4 H L A - D R. - - , c C D 3, c C D 7 9 a, c C D 2 2, C D 2, CD7, CD19 [14, 206].

( F A B - 1). - . , , , C D 1 3, C D 3 3, C D 1 1 7, / . CD34, CD11b CD14 [14] 1 2 (. 71).

V io To" io io io if f*.0 2 3 1 2 To io' IO IO IO "To" 0 2 3 Mo M I | G 1 IO 111 IB* IO 1 2 CDJ5 FITC FITC CTW FITC \ % J 3 "

7o 10 10 IO III 2 IO io io in 1 2 FITC com e e J :* "s m ~ ^

IO IO IO IO ~0 1 2 3 III To" io io io ~o iu' io iu io IO IO 2 3 0 1 2 3 C D 2 FITC CDIS FITC SlgM x= 0 ml HI "To" ' IO IO IO io io 2 3 4 2 3 0 2 0 0 4011 Mm To io io io io 0 1 2 3 Tdi FITC CJ IgM Forward Seiner MPOFITC . 7 1. .

( F A B 2) (. 7 2 ). 2 CD 13, CD 33, C D 1 5, C D 1 1 7, C D 3 4, H L A D R [ 1 4, 37, 2 0 8 |.

3545 % 2 t(8;

21)(q22;

q22). (CD 13, CD 33, ), 2 t(8;

21) ­ C D 1 9 [208]. C D 3 4, C D 5 6 TdT. , t(8;

21), C D 2 C D7.

= 4.

'= K% t-I h S" t ll 2 T.

!

1 1~ ~ # f W 7o 7o io' io' 10' IO IO IO I0 IO IO IO 2 1 IO ! 3 2 10 IO II 0 1 2 M l FITC Mom* I t G I CDJ FITC CD-I F I T C 14 b - " h* " e*j| -* !

_ \ \ % 7o" 7o 10' IO IO IO io' io io io 7o 7 0 2 5 in 2 3 IO | IO IO 3 1 IO IO =.

3 1 Mil 020 D J 4 F H C C D 7 FITC C'DIOFITC 1 h e '= jl 1 i % %, " 7o 7o 1 F* 7 1 io io io io IO IO 2 IO IO 1 1 2 3 IO 10* 1 I 1 1 2 IO IO IO IO 2 CBismt KM FITC cm* cm FiT e e f I! L ~= e % L 7o z io io io io 7o 2 3 io io io io 7o 200 400 600 Mm 1 2 3 IO IO IO IO 1 2 3 MM-I,.|K-I. M I I J.. - ). M II \in.

FSC-Hrithl 1,4 FITC TdT . 72 - 2 : , . C D 1 3, C D 3 3, C D 3 4, C D 6 5, H L A - D R, . .

, , C D 2 C D 7. , , . , , - . , , , , [206].

( t( 1 5 ;

1 7 ) ( q 2 2 ;

q 1 2 ) ;

{PMURARa) ). (. 73) , C D 1 3, C D 3 3, CD9, CD34 HLA-DR, C D 1 5, C D 3 4 0 - 4 5 % , M 3 v, - CD2 [209].

h "4 I h "= g " io* iff* io I 1 To IO IO IO 1 2 0 IO IO IO IO 1 2 3 ~o io' IO 10 2 3 ., I,-CI CD45 FITC CDJ FITC CDJ FITC \ t ~ 2 b r a~ s" To io' io io io 0 2 3 ~o io' IO IO IO 2 3 IO 111 IO 1 2 CD20 FITC CDIOFTTC CD7 FITC " " -= %O To" I IO IO IO V 1 2 3 IO IO 10 IO 1 2 3 10 10* IO 10 IO 2 3 CDI5 U K CDI9 FITC slgM [ 1 I To" io' io io IU A n l i - M, IMPOI FITC 200 400 600 800 KM -Height . 73. 3. - , 1 2. M3v 4 5 [210, 211].

( F A B 4). ( 74) , . (CD 13, CD33) , (CD 14, CD 4, CD 11b, CD 11c, CD 36, CD64 ).

\ 5 '=

~ "ill" ' io io 1(1 3 3 III' IO I IO 2 io' 2 IO IO ( F I I C IgGl RIC i in I M S FT 8** "io" 10 0 " 2 3 4 2 3 IO IO IO IO IO IO IO IO IO IO 1 2 3 2 3 IO IO IO (1)7 U K (1)20 COJ4 F I T C MIL ('DM FIIC e ' 10 10 10* s IO To" ' io- in IgM io" io" io- io ( 1)2 F I T C CDI5 FITC I ] 1^1

To" 10 1 io' IO IO 2 4 :on hoo mm loon IO IO 0 2 TdT F I T C " 4rto|ceiiiW.LROLHI( .- ] II, I In S . 74. 3.

- 4. inv(16)(p13q22) t ( 1 6 ;

1 6 ) ( p 1 3 ;

q 2 2 ) ;

(CBFpVMYHH) [14], 4 , - C D 2 [ 2 1 2 ], ',,- io * I0 2 "" I0 10* CD4S

I t" s i \ ~o io' io io io io IO I0 10 IO 10 10* 2 3 1 2 IO IO IO* 1 Ml' 1 2 2 CD' Mil CDJ4 11 \ it " 5" IO IO IO 10* 1 2 CD2 FITC IO IO IO 10* 1:4 HI' 1 2 CDI4 KMC CDI5 FITC " I I I: it " n s lull 4 0 0 600 M IOOO ' io io io* io' IO IO 2 3 I I I Scatter IO I IT' TdT FITC 1 c,l|M MFOI'IIC . 75. .

- ( F A B - 5) ( F A B - 5 ). 5 (. 75) C D 1 4. C D 4. C D 1 1 b, C D 1 1 , C D 6 4, C D 6 8, C D 1 5, C D 3 6, , C D 5 6 C D 3 4 , C D 1 3, C D 3 3, C D 1 1 7 . - . CD14 , 5 .

C D 4 1 a C D 6 1 - llb/llla. 5 7, . , , C D 6 8 [14].

( F A B - ). . - . , [210] .

(-) - - , . C D 1 3, C D 3 3, C D 1 1 7 (c-kit) [14].

. , H L A - D R C D 3 4. , , . , (car bonic a n h y d r a s e 1, G e r o - ). - C D 36 , C D 3 6 [14].

, 7, , , , , . C D 4 1 a, C D 4 2 b, C D 6 1, .

, , [ 2 1 0 ]. - , - , - - . 1 [14].

[14].

(7). 7 0 - 1 , . : C D 4 1 a / C D 6 1, C D 4 2. C D 13 C D 3 3 , CD34, HLA-DR , . CD36.

70 % C D 7 C D 2. - , [ 1 4, 2 0 6 ].

, , 7 [14].

- , . - , ( . 7 6, 77).

, . , . 4 % [213].

, , 0,5 2 . . 16 , E G I L - 9 5 [53]. , ( ) .

(EGIL-95) [53] - - cy/s CD3, anti-TCR 2 CD79a*, cylgM, cyCD22 anti-MPO a/p, anti-TCR lb 1 CD19, CD10, CD20 CD2,CD5,CD8,CD10 CD13, CD33, CD65s, CD14, CD15, CD64, 0,5 TdT, CD24 TdT, CD7, CD1a CD . , 2 .

*CD79a / -.

l\ h J 1 ~o IO IO IO IO 1 2 3 ~o io' IO IO IO io" io- io" io" li.1 I I T I CD4S F I T C 2 3 rnx DJ 1% s" "s io" io io I ~o io' IO IO IO 1 2 10 10* 2 To ' n ^ io IO IO IO 0 2 2 3 C R M FTTf CDIOFTTC CD7 F I T C FTTC s U IO IO IO 7o io' 1 2 "0 10 IO IO IO IO 10' 10 4 2 CD2 F I T C ( DIMIFC FIIC OH FTTC = ~o io' io io io "0 IO IO IO IO 1 2 3 II 200 400 600 Mill ] 2 3 "0 IO IO IO 1 2 TdT Fill Forward ScNlttT "KM MPDIIII . 76. .. 5 .

- ( + -) _ -r_ % t\ h ac Jl a " X ii " oo " 3 % 10 ' E i i i "o ' o o o = it io 1 1l "0 IO Iff Iff I 0 1 2 5 2 J 2 3 CD4 D45 FTTC lo" MF DJ FITC "= | " h I* _ i = J ' " 3 "io 10' ~ 1 IO IO* I ' To 2 3 IO IO IO ( DJ4FFTC =.

D20FITC (D'HTC 4 "" I0 io IO ' s 1 h " k r w U -= ~ -_ ' "o T" ' - ' M 7a" ' -* 2 IO IO 3 2 IO 2 3 4 s Ill'Ullt n: FiTf " io '= C D 15 FTTC aunt ~ "fc " h 1 1% 0 himi 4 ii ) :i i " n io ' V t n * 1 I

2 3 ol|M 1 V

it if* it 1 77 I T * l. l M.,1 ò TdT F i.Mill - ( +-) - - - [ 2 1 4, 2 1 5 ]. .

- : 1) ;

2) ;

3) [ 2 1 6 ].

, fusion- , . , , (core binding factors - CBFs). , , - [ 1 5 8 ].

8 0 - 8 5 % , F A B - ( . 17).

[114] / no FAB- , % 1 2 t- t(11;

22)(q23;

q13) 1 11q23/WLL 22q1 Dz t(8;

21)(q22;

q22) 14 2.1 21q22/AMLf 8q22/ETO t(11;

17)(q23;

q21) 1 , variant 11q23/PLZF 17q12-21/RARA t(11,17)(q13;

q21) 11q13//VuMA 17q12-21/RARA 1 , variant t(11;

17)(q23;

q21) 11q23/MLL 17q21/AFf 1 4. t(1;

22)(p13;

q13) 1 7 t(9;

11)(p22;

q23) 7 4.5 9p22/AF9 11q32/MLL t(9;

9)(q34;

q34) 1 9q34/CA/V 9q34/S t(6;

11)(q27;

q23) 1 4,5 6q27/AF6 11q23/MLL t(6;

9)(p23;

q34) 2. 1 6p23/DK 9q34/CA/V t(1;

11)(p32;

q23) 1 4.5 1p32/AF7p 11q23/MLL t(1;

11)(p32;

q23) 1 4.5 1q21/AF,g 11q23/MLL t(15;

17)(q22;

q12-21) 15q22/pm/ 17q12-21/RA RA 8 t(15;

17)(q34;

q12-21) 1 ,variant 5q34//VPM 17q12-21/RARA t(X;

11)(q13;

q23) Xq13/AFX?

1 4.5 11q23//WlL t(10;

11)(p12-14;

q23) 1 4;

5 11q23/MLL 10p12-14/AF inv(3)(q21;

q26) 1 Zq2-\Ribophorin1 3q26/VJ t(10;

11)(p12-14;

q14-21) 1 10p12-14/AF,0 11q14-21/CAWL . 1 2 inv(16)(p13.1q22),t(16;

16) 10 M4 Eo W3MMYH11 | 16q22/C6F 7 del(7q) 4 M2.M4 3q25.1/MLFt 5q34//VPM t(3;

5)(q25.1;

q34) 811.2/MOZ 16p13.3/CBP t(8;

16)(p11.2;

p13.3) 1 M4;

M t 11q23/MLL 16p13.3/CSP t(11;

16)(q23;

p13.3) M4.M5 11q23/MLL 1913.3/.

t(11;

19)(q23;

p13.3) 11q23/M.L 19p 13.1/ELL t(11;

19)(q23;

p13.3) 1 M4.M t(16;

21)(p11.2;

q22) 1 16p11.2/7LS 21q22/RG 22q11.2/M/Vr t(12;

22)(p13;

q11.2) 1 12p13/7EL t(3;

3)(q21;

q26),inv(3) (q21q26),ins(3) 3q26IEV11 (q21;

q25q27) 3q26/AP/MDS/ t(3;

21)(q26;

q22) 1 21q22//WL EV 3o2QIEAP/MDS/ t(3;

12)(q26;

p13) 1 12p13/7EL EV inv(11)(p15.5q22) 11p15.5//vl/P98 11q22/DDXfO , ǭ (t(8;

21);

inv(16);

t(16;

16);

t(15;

17), 11q23) [14, 2 1 7 ].

t ( 8 ;

2 1 ) ( q 2 2 ;

q 2 2 ) (AML1/ETO) (. 78). 40 % 2 F A B , 6 % 1, 7 % 4 [ 1 1 7 ] ;

6, del(9)(q34) , , , , [218, 2 1 9 ].

t ( 8 ;

2 1 ) ( RUNX1 CBFa ) 2 1 q 2 2 , 8 q 2 2 AML1/ETO ( .


79) [ 1 3 5, 1 3 9 ]. () : G M C S F (̭), C S F 1 R ( ), TCRb ( ҭ ), . , CD 34+ . AML1/ETO .

AML1/ETO t(8;

21) , 510 % / / t(8;

21) , , , . |219].

\ 1 I 1 * 7 8 ^ 1 II 4I II ' II I* 1. 13 78 , 10 (. 2) 45,X,-Y,t(8;

21)(q22;

q22).del(9)(q12q32) I 2 3 4 79 AML1/ETO: 1 - ;

- (PMURARa) t(15;

17)(q22;

q12) ( . 8 0, 81) | 1 1 7, 135, 2091 : 1 5 q 2 2 - PMURARa, 1 7 q 2 1 - RARa/PML. - , t(15;

17) 1 0 0 % PMURARa P/WL- - - RARa. , P M L / R A R a , , - . , PML/RARa - P M L, , .

1 * ft X 1 ;

% ** * . 18 '

13 17 - 21 X 80 ., 5 (. ) 46,XX.t(15;

17)(q22;

q21) 1 - + . 8 1. PML/RARa: 1 - ;

- - ;

+ - .

- : t ( 1 1 ;

1 7 ) ( q 2 3 ;

q 2 1 ) ( RARa PLZF), t ( 5 ;

1 7 ) ( q 3 2 ;

q 1 2 ) ( RARa NPM), t ( 1 1 ;

1 7 ) ( q 1 3 ;

q 2 1 ) ( RARa NuMA). t(11;

17), , [14].

, PMURARa t ( 1 5 ;

1 7 ), t(15;

17) A T R A [ 1 9 4 - 1 9 9, 2 0 9 ] PML/RARa , [ 2 0 9, 2 1 1 ]. PML/RARa , , - , .

inv(16)(p13q22) t(16;

16)(p13;

q22);

( C B F P / M Y H 1 1 ) ( 82, 83). 4 . F A B - (2. 4, 5). CBF/3, 16q22, MYC11, 1613 C8F/3 , - - CBF ( 2). - MYH - - CBF/3/MYH11 [220|.

!! U it I I I( 82 ., 10 (, 4):

47, XX, +8, inv(16)(p13q22) . 83. CBFfi/MYHH HemaVision ( ) , CBF/3/MYH inv( 16) 7 5 % | 2 2 1 |, , , F I S H , .

11(q23) ( M L L ) 11 q 2 3 t(9;

11)(p21;

q23) ( 84) t(11;

19)(q23;

p13.1)/ t(11;

19)(q23;

p13.3), 7 2 % . 20 , , t ( 6 ;

1 1 ), t ( 1 0 ;

1 1 ) t ( 1 ;

1 1 ) ( 8 5 - 8 8 ), 11 ( q 2 3 ). , MLL , .

1!

** 6 % 1 Z II *? 2 II !

/ 13 1S 1 * 19 2 21 Z2 X . 84 3., 1 (, 5): 46,XX.t(9:11)(p21;

q23) 1 3 1 1 I I XI * ii 7 9 18 6 * * * ft 1 1 17 || g v g * * 19 2D 21 . 85 . 5 ( 4):

46,XX,t(1;

11)(q21;

q23) U % l Hi 7 8 9 1 ^, I :' 1 15 16 17 IB | * V | | 28 21 19 X V . 86 ., 1 ( 4):

46,XYqh++.t(2;

11)(p21;

q23) ill }l H Hi I i H II U UUJ III 6 ^ 7 9 11 IB A ftA I if I IA :'m Ii 13 14 15 16 17 87 , 17 ( ) 51,XX.+4.t(6;

11 )(q27;

q23).+6.+8.+21 + it ̻ X S S3 s 6 7 9 IB II N S 88 ., 17 ( 2):

46,XX.der(10),t(10;

11)(p12;

q23),inv(11)(q21q23),der(11),t(10;

11)(p12;

q21) , , ( ) , , , 4 5 . 11(q23) | 1 3 5 |. t(9|11) 5 [117].


t ( 1 ;

2 2 ) ( p 1 3 ;

q 1 3 ) ( 89) ( 7) , , 1-3 % MAL 2 2 q 1 3 113 OTT-MAL t(1;

22) [14] 7 [14].

us 1 1 1 II II s* * 18 11 IZ ft J.

#6 * * * # 14 U lb VI 19 28 . 89. ., 1 ( 7):

57,XY,t(1;

22)(p13;

q13),del(1)(p13),del(1)(q23), +2,+5,+6.+7,+10,+15,+19,+21,+21,+21,+ . , 50 ( 8 7, 89) , , 8 (. 90), 1 0 % . 8 . 4, 9, 10, 11, 13, 2 1 22 , | 2 1 1 |. 21- ( ) (. 91) ( 7) 2 0 , [ 1 1 7 ].

2 1 11! -i t tr 18 | ft ft IS (

* X 19 . 90. ., 15 ( 4): 47, XX, + U II II 1 Z 1 1 s II 1 it 1 7 t ft .

1 1 13 I * - | X 91 ., 6 ( , 7): 46, XX, + 7 (7) (. 92) 7 (7q) | 2 2 2 |. 7 . 7. . 7 q , , q 2 2 7, | 2 2 3 ].

it I* II ;

,*.* 2 S t S I II 1 I 1 II 7 9 18 II 4* At * 13 15 16 17 - ) 19 28 21 22 X . 92. ., 8 ( 1): 45, XY, Y ( . . 78) t(8|21) , . t ( 9 ;

2 2 ) , t ( 9 ;

2 2 ;

10), 1 7 4 1 % [102, 224, 225]. , 11q23 [102, 225]. , , d e l ( 6 q ) 1 2 1 1. 2 10 % [4]. : t ( 2 ;

6 ) ( q 3 7 ;

p 2 1. 3 ) [225], t(8;

14)(p21;

q32) [225], t(8;

21)(q22;

q22) [102], t(9;

12)(q1;

q1) [226], t ( 1 4 : 1 9 ) ( q 3 2 ;

q 1 3. 1 ) [ 2 2 7 ], t ( 1 5 ;

1 7 ) ( q 2 2 ;

q 2 1 ) [ 2 2 8 ], inv( 1 6 ) / 1 ( 1 6 ;

1 6 ) [ 2 2 9 ].

, , . , .

, , , , ( 5 % ) . . , - , [230-235]. . , / T C R 1, - , .

1. I n t e r n a t i o n a l I n c i d e n c e of C h i l d h o o d C a n c e r : I A R C Scientific Publications / D. P a r k i n [et al.]. - L y o n, 1998. - 144 p.

2. , O B. 1989 2 0 0 3 / .. , . . , . . // : : . . . II . .-.

., , 2 6 - 2 7 2 0 0 4 . - , 2 0 0 4. - . 1 0 - 1 2.

3. , . / . . . . . - : , 2 0 0 4. - 170 .

4. A s y s t e m of provision, p r e s e n t a t i o n a n d i n t e r p r e t a t i o n o f d a t a o n c a n c e r inci d e n c e a n d s u r v i v a l of c h i l d r e n a n d a d o l e s c e n t s in E u r o p e // A u t o m a t e d C h i l d h o o d C a n c e r I n f o r m a t i o n S y s t e m ( A C C I S ) [Electronic r e s o u r c e ], - 2 0 0 7. - M o d e of a c c e s s :

http://www-dep.iarc.fr/accis.htm.

5. G e o g r a p h i c a l patterns a n d t i m e t r e n d s o f c a n c e r i n c i d e n c e a n d survival a m o n g c h i l d r e n a n d a d o l e s c e n t s in E u r o p e s i n c e t h e 1 9 7 0 s ( t h e A C C I S project): a n e p i d e m i o l o g i c a l study / E. S t e l i a r o v a - F o u c h e r [et al.]. - L a n c e t, 2 0 0 4. - V o l. 3 6 4. P. 2 0 9 7 - 2 1 0 5.

6. C a n c e r s u r v e i l l a n c e s e r i e s : recent t r e n d s in c h i l d h o o d c a n c e r i n c i d e n c e a n d m o r t a l i t y in t h e United S t a t e s / M. Linet [et a l ] // J. of t h e N a t i o n a l C a n c e r Institute. 2 0 0 3. - V o l. 9 1 ( 1 2 ). - P. 1051-1058.

7. C a n c e r incidence a m o n g children in F r a n c e, 1 9 9 0 - 1 9 9 9 / E. D e s a n d e s [et al.] // Pediatr. B l o o d C a n c e r. - 2 0 0 4. - V o l. 4 3. - P. 7 4 9 - 7 5 7.

8. C h i l d h o o d c a n c e r a m o n g A l a s k a N a t i v e s / A. L a n i e r [et a l ] // Pediatrics. 2 0 0 3. - V o l. 112. - P. 3 9 6 - 4 0 3.

9. U r b a n i z a t i o n a n d c h i l d h o o d l e u k e m i a in T a i w a n / C h. Li [et al.] // International J. o f E p i d e m i o l o g y. - 1998. - V o l. 2 7. - P. 5 8 7 - 5 9 1.

10. 2 0 : . / . .. , .. ;

. - , 2006. 1 1 2 .

1 1. I n c i d e n c e of l e u k e m i a in children from E l S a l v a d o r a n d M e x i c o City b e t w e e n 1996 a n d 2 0 0 0 : P o p u l a t i o n - b a s e d d a t a / J. M e i f a - A r a n g u r e [et al.] // B M C C a n c e r. 2 0 0 5. - V o l 5. - P. 33-42.

12. M a t h e, G. Histological a n d cytological typing of neoplastic d i s e a s e s h e m a topoietic a n d l y m p h o i d t i s s u e s / G. M a t h e, H. R a p p a p o r t // International h i s t o l o g i c a l classification of t u m o u r s. - G e n e v a : W o r l d Health O r g a n i z a t i o n, 1 9 7 6. - N o. 1 4.

13. P r o p o s a l s for the classification of t h e a c u t e l e u k e m i a s. F r e n c h - A m e r i c a n British (FAB) C o o p e r a t i v e G r o u p / J. M. B e n n e t [et al.] // Br. J. H a e m a t o l. - 1 9 7 6. Vol. 3 3. - P. 451-458.

14. W o r l d Health O r g a n i z a t i o n Classification of T u m o u r s ;

P a t h o l o g y a n d G e n e t ics of T u m o u r s of H a e m a t o p o i e t i c a n d L y m p h o i d T i s s u e s / Edited by E. Jaffe [et al.]. F r a n c e, L y o n : I A R C Press, 2 0 0 1. - 3 5 1 p.

15. V a r d i m a n, J.W. T h e W o r l d Health O r g a n i z a t i o n ( W H O ) classification of t h e m y e l o i d n e o p l a s m s / J.W. V a r d i m a n, N.L. Harris, R.D. B r u n n i n g // B l o o d. - 2 0 0 2. Vol. 1 0 0. - P. 2292-2302.

16. , .. / .. . - ., 2000. - 248 .

17. L a n z k o w s k y, P h. M a n u a l o f Pediatric H e m a t o l o g y a n d O n c o l o g y, 3 e d. / nd Ph. L a n z k o w s k y. - C h u r c h i l l L i v i n g s t o n e Inc., 2 0 0 0. - P. 3 5 9 - 4 1 3.

18. Pui, C.-H. A c u t e lymphoblastic leukemia / C.-H. Pui, W. M. Crist;

ed. C h. - H. Pui // Childhood Leukemias. - N.Y.: C a m b r i d g e University Press, 1999. - P. 2 8 8 - 3 1 2.

19. A c u t e m y e l o i d l e u k e m i a : I n c i d e n c e a n d o b s e r v e d survival in c h i l d r e n of B e l arus / N. S a v v a [et al.] // C h i l d h o o d l e u k a e m i a. I n c i d e n c e, c a u s a l m e c h a n i s m a n d p r e vention: International Scientific c o n f e r e n c e. - L o n d o n, 2 0 0 4. - P. 2-6.

20. 1 A L L - B F M 9 0 / .. [ . ] // : V ;

. . . 7 0 - . - , 2 0 0 3. - . 1. . 2 1 8 - 2 2 0.

2 1. / . [ . ] // . - ., 2 0 0 2. - . 4 7, 2. - . 4 2 - 4 22. / . [ . ] // . - ., 2 0 0 2. - . 4 7, 3. - . 3 0 1 - 3 0 5.

23. Pui, . . C h i l d h o o d acute lymphoblastic leukemia - current s t a t u s a n d future perspectives / C. H. Pui, D. C a m p a n a, W. Evans // Lancet O n c o l. - 2 0 0 1. - V o l. 2. P. 5 9 7 - 6 0 7.

2 4. Results of t r e a t m e n t of c h i l d r e n with refractory a n a e m i a w i t h e x c e s s blasts ( R A E B ) a n d R A E B in t r a n s f o r m a t i o n ( R A E B t ) in G B 1 9 9 0 - 9 9 / D. K. H. W e b b // Br. J.

H a e m a t o l. - 2 0 0 2. - V o l. 1 1 7. - P. 33-39.

2 5. P o s t r e m i s s i o n t h e r a p y for c h i l d r e n with a c u t e m y e l o i d l e u k e m i a : the c h i l dren's c a n c e r g r o u p e x p e r i e n c e in t r a n s p l a n t era / . A l o n z o [et al.] // L e u k e m i a. 2 0 0 5. - V o l. 19. - P. 9 6 5 - 9 7 0.

26. , .. : ( -) / .. , .. , . // , . - 2 0 0 4. - 4. - . 14-20.

2 7. B i o n d i, A. M o l e c u l a r d i a g n o s i s a n d m o n i t o r i n g of a c u t e m y e l o i d l e u k e m i a / A. B i o n d i, A. R a m b a l d i / / L e u k e m i a R e s e a r c h. - 1 9 9 6. - V o l. 2 0, n o. 10. - P. 8 0 1 - 8 0 7.

28. S h i m o n i, A. A l l o g e n e i c h e m a t o p o i e t i c s t e m - c e l l t r a n s p l a n t a t i o n in patients with a c u t e m y e l o i d l e u k e m i a in first c o m p l e t e r e m i s s i o n : n e w a n s w e r s for a n d old q u e s t i o n / A. S h i m o n i, A. Nagler // L e u k e m i a. - 2 0 0 5. - V o l. 19. - P. 8 9 1 - 8 9 3.

2 9. R o w l e y, J.D. C h r o m o s o m e t r a n s l o c a t i o n : d a n g e r o u s liaisons / J.D. R o w l e y // J. L a b. C l i n. M e d. - 1 9 9 8. - V o l. 132, no. 4. - P. 2 4 4 - 2 5 0.

3 0. G e n e e x p r e s s i o n profiling of pediatric a c u t e m y e l o g e n o u s l e u k e m i a / M.E. R o s s [et al.] // B l o o d. - 2 0 0 4. - V o l. 104, n o. 12. - P. 3 6 7 9 - 3 6 8 7.

3 1. C l a s s i f i c a t i o n, s u b t y p e discovery, a n d p r e d i c t i o n o f o u t c o m e in pediatric a c u t e l y m p h o b l a s t i c l e u k e m i a by g e n e e x p r e s s i o n profiling / E.J. Y e o h [et al.] // C a n cer C e l l. - 2 0 0 2. - V o l. 1. - P. 1 3 3 - 1 4 3.

3 2. I m p a c t of i m m u n o p h e n o t y p i n g o n m a n a g e m e n t of a c u t e l e u k e m i a s / M B e n e [et a l. ] / / H e m a t o l o g i c a. - 1 9 9 9. - V o l. 8 4, n o. 1 1. - P. 1 0 2 4 - 1 0 3 4.

3 3. J a m s h i d i, K. B o n e m a r r o w biopsy w i t h u n a l t e r e d a r c h i t e c t u r e : a n e w biopsy d e v i c e / K. J a m s h i d i, W. R. S w a i n // J. Lab. C l i n. M e d. - 1 9 7 1. - V o l. 77. - P. 3 3 5 - 3 4 2.

3 4. N e i d h a r d t C a n c e r in Children / P.A. V o u t e [et al.]. - B e r l i n, H e i d e l b e r g, N e w Y o r k, T o k y o : S p r i n g e r - V e r l a g, 1990. - P. 129.

3 5. W o l m a n, I.J. Laboratory a p p l i c a t i o n s in clinical P e d i a t r i c s / I. J. W o l m a n // L o n d o n : M c G r a w - H i l l B o o k C o., Inc., 1 9 7 7.

36. K i n n e y, C M. Classification a n d differentiation o f a c u t e l e u k e m i a s / C. M. K i n n e y, N.J. L u k e n s ;

ed. G.R. Lee // W i n t r o b e ' s clinical h e m a t o l o g y, 1 0. -,h 1 9 9 9. - P. 2 2 0 9 - 2 2 4 1.

3 7. H e c k n e r, F. P r a c t i c u m der m i c r o s k o p i s c h e n H e m a t o l o g i e / F. Heckner. M u n c h e n - W i e n - B a l t i m o r e : U r b a n a n d S c h w a r z e n b e r g, 1994. - 130 p.

38. W i l l i a m s, M. G. Clinical H e m a t o l o g y, 5 / M. G. W i l l i a m s, B.S. Coller;

e d,h L o n d o n : M c G r a w - H i l l Inc. - 1 9 9 5. - 1581 p.

3 9. P e r k i n s L.S. E x a m i n a t i o n of the b l o o d a n d b o n e M a r r o w // W i n t r o b e ' s clini cal h e m a t o l o g y. - 10 e d / G. R. L e e. - 1999. - P. 9 - 3 6.

40. : , / . . [ . ]. - : , 2 0 0 1. - 4 3 .

4 1. , S.J. I m m u n o p h e n o t y p i n g of l e u k e m i a by flow c y t o m e t r y. C l o s i n g the black h o l e s of m o r p h o l o g y / S.J. // Bull C a n c e r. - 1 9 9 5. - V o l. 8 2. - P. 1 1 7 - 1 2 1.

4 2. S u l i v a n, J.G. I m m u n o p h e n o t y p i n g of leukemia, the n e w force in h e m a t o l o g y / J. G. S u l i v a n, . W i g g e r s // Clin. L a b. S c i. - 2 0 0 0. - V o l. 13. - P. 1 1 7 - 1 2 2.

4 3. M o r p h o l o g i c, i m m u n o l o g i c a n d c y t o g e n e t i c c l a s s i f i c a t i o n of a c u t e m y e l o i d l e u k e m i a a n d m y e l o d y s p l a s t i c s y n d r o m e in c h i l d h o o d : a report f r o m Children's C a n c e r G r o u p / D R. B a r n a r d [et a l ] // L e u k e m i a. - 1 9 9 6. - V o l. 10. - P. 5 - 1 2.

4 4. G a t i n g strategy for i m m u n o p h e n o t y p i n g of l e u k e m i a a n d l y m p h o m a / S.R. T s i e s h [ e t a l. ] / / A m. J. Clin. Pathol. - 1997. - V o l. 108. - P. 1 5 2 - 1 5 7.

4 5. , .. / . , .. // , - 1 9 9 2. - 1. . 1 5 - 2 1.



Pages:     | 1 | 2 || 4 | 5 |   ...   | 8 |
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .